Duchenne muscular dystrophy+1
Not yet recruitingStudy on the Safety and Effectiveness of Delandistrogene Moxeparvovec for Patients with Duchenne Muscular Dystrophy
Study on the Safety and Effectiveness of Delandistrogene Moxeparvovec for Patients with Duchenne Muscular Dystrophy
- Disease:Duchenne muscular dystrophyDuchenne muscular dystrophy gene carrier
- Substances:Delandistrogene Moxeparvovec
France- Participants:0–17 years · 18–64 years
- Substances:Delandistrogene Moxeparvovec
- Sponsor:Sarepta Therapeutics Inc.







